Nxera Pharma Revises FY2026 Forecast
Nxera Pharma forecasts FY2026 net sales of JPY 48.80 billion, core operating income of JPY 22.80 billion and operating income of JPY 15.70 billion.
Related stories
Glanbia Raises FY2026 Adjusted EPS Growth Guidance to 22%-24%
Glanbia reported 9.9% like-for-like revenue growth for the nine months ended October 3, 2026, with volume up 4.2% and pricing up 5.7%. It raised full-year 2026 adjusted EPS growth
M impact | EARNINGS | Nov 04, 2026, 09:33 AM UTC
Prosegur Reports Higher January–September Profit and Revenue
Prosegur reported increases in profit and revenue for the January–September period.
M impact | EARNINGS | Nov 04, 2026, 09:33 AM UTC
Cathay Real Estate Reports Jan-Sept Net Profit of T$3.34 Billion
The company reported net profit of T$3.34 billion, or T$2.88 per share, for January through September.
M impact | EARNINGS | Nov 04, 2026, 09:33 AM UTC
AIB Group Reports Nine-Month Results, Raises FY26 Net Interest Income Guidance
AIB Group reported nine-month net interest income up 2% year over year and total income up 3%. It upgraded its FY26 net interest income guidance.
M impact | EARNINGS | Nov 04, 2026, 09:32 AM UTC
Autohome Reports Q3 Net Income of RMB 195 Million
M impact | EARNINGS | Nov 04, 2026, 09:31 AM UTC
Sinyi Realty 3Q Net Profit Rises to NT$192.6M
Sinyi Realty reported third-quarter revenue of NT$2.82962 billion and pretax profit of NT$247.466 million. A year earlier, revenue was NT$2.304144 billion and pretax profit was NT$
M impact | EARNINGS | Nov 04, 2026, 09:31 AM UTC